

# AeroChamber

Plus **Flow-Vu**®

Anti-Static Valved Holding Chamber

# Better Together.



 monaghan®



SAME PRODUCTS.  
NOW DIRECT FROM THE MANUFACTURER.

# MONAGHAN MEDICAL CORPORATION

153 Industrial Boulevard | Plattsburgh, NY 12901

## State-of-the-Art Manufacturing Facility | November 2020

- Moved to a new 65,000 sq ft manufacturing facility in Plattsburgh, New York
- Doubled our operational size, inventory capacity and production facilities
- Property allows for future expansion of both product and manufacturing capacity



## OUR MANUFACTURING PROCESS:

MOLDING

PRODUCT DESIGN


QUALITY IMPROVEMENTS

RESEARCH & DEVELOPMENT

DISTRIBUTION

PROTOTYPING/  
EVALUATIONS

# Despite the continuous innovation of inhaler devices, patient technique has not improved over time.<sup>1</sup>





# Chambers are proven to deliver medication *better* than the inhaler alone.<sup>4,5,6</sup>




# Chambers *overcome* coordination issues.<sup>7</sup>

If using an MDI alone, even a short half-second delay reduces the prediction lung delivery to approximately 1% of the intended dose. The AEROCHAMBER<sup>®</sup> device holds the medication suspended for an extended period, allowing patients more time to inhale their medication.



# Validated Safety and Efficacy

AEROCHAMBER PLUS® brand of chambers delivers the intended dose established by the pharmaceutical company. Other chambers cannot make this claim, because they deliver less, meaning patients are wasting expensive medication and may not be receiving the optimal therapeutic dose.<sup>8,9,10</sup>



# Each Valved Holding Chamber + MDI combination should be considered a unique delivery system


Many chambers claim to be equivalent to the AEROCHAMBER PLUS® FLOW-VU® chamber but they are not. Differences in VHC design (shape, size, valves) have an impact upon drug delivery – there is a potential risk of interchanging without understanding the impact this has.

Advair	Bevespi	Ipravent	Seretide	Ventolin
Alvesco	Combisol	Kelhale	Sirdupla	Zenhale
AirFluSal	Flovent	Luforbec	Symbicort	
Atrovent	Flutiform	Qvar	Trimbow	
Avenor	Fostair	Sereflo	Trixeo	

**PRESCRIBE AS WRITTEN. DO NOT SUBSTITUTE.**

# Different chambers deliver different amounts of medication<sup>11,12</sup>

Predicted delivery of medication to the lungs with the AEROCHAMBER PLUS® FLOW-VU® chamber was **almost double** that of the other chambers tested.<sup>13</sup>



Guidelines recommend use of chambers for people of all ages.

For patients who have trouble coordinating inhalation with device actuation, the use of a chamber (with a valve) may obviate this difficulty. The use of chambers is mandatory for infants and young children.


American College of Chest Physicians (ACCP)/  
American College of Allergy | Asthma & Immunology  
2005

For patients prescribed pressurized metered dose inhalers (pMDIs) use of a chamber improves delivery and (for ICS) reduces the potential for local side-effects such as dysphonia and oral candidiasis.

Global Strategy for Asthma Management and  
Prevention 2021 | Global Initiative on Asthma.  
www.ginasthma.org









*People who use a chamber with their inhaler have been shown to have better asthma control.*<sup>14</sup>

# Ensure inhaler medicine gets to the lungs, where it's needed.



Inhaler Alone

Inhaler with AEROCHAMBER PLUS®  
FLOW-VU® aVHC

	WAC SWP	UPC	Part Number	Package Size	UOM	Case Size
 <b>Small Mask</b>	\$49.04 \$58.85	 6 043 51 501 12 6	50112	1	EACH	12
 <b>Medium Mask</b>	\$49.04 \$58.85	 6 043 51 502 12 3	50012	1	EACH	12
 <b>Mouthpiece</b>	\$36.37 \$43.64	 6 043 51 500 12 9	50212	1	EACH	12
 <b>Large Mask</b>	\$49.04 \$58.85	 6 043 51 503 12 0	50312	1	EACH	12



153 Industrial Boulevard, Plattsburgh, NY 12901  
 +1-800-833-9653 | customerservice@monaghanmed.com  
 monaghanmed.com



1. Chart adapted from Sanchis J et al. Chest 2016. 2. GINA Global Strategy for Asthma Management and Prevention, 2021. and Melani A et al. Respiratory Medicine 2011;105:930-938. 3. GINA Global Strategy for Asthma Management and Prevention, 2021. 4. Dorinsky P et al. Clin Ther. 42 (2020), 634-648. 5. Suggett J et al. Am J Respir Crit Care Med 2020;201:A5689 6. Suggett J et al. DDL 28, Dec 2017. 7. Suggett J et al. Am J Respir Crit Care Med 2020;201:A5689 8. Harkness H, et al. CRC 2012. 9. Nagel M, et al. CSACI 2017. 10. Dissanayake S et al. Pulmonary Pharmacology & Therapeutics 2018;48:179-184. 11. Medicines and Healthcare Products Regulatory Agency (MHRA). Drug safety update – inhaled products that contain corticosteroids, July 2008. 12. Global initiative for asthma (GINA) guidelines, 2021; Global strategy for asthma management and prevention. 13. Suggett J et al. European Respiratory Journal 2020;56:4015. 14. Levy ML, Hardwell A, McKnight E, Holmes J. Prim Care Respir J. 2013; Dec;22(4):406-11. TM/® trademarks and registered trademarks of Monaghan Medical Corporation (MMC). © MMC 2023. All rights reserved.